United Therapeutics Corporation - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

United Therapeutics Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'United Therapeutics Corporation - Product Pipeline Review - 2015', provides an overview of the United Therapeutics Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of United Therapeutics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of United Therapeutics Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of United Therapeutics Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the United Therapeutics Corporation's pipeline products

Reason to Buy

- Evaluate United Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of United Therapeutics Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the United Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of United Therapeutics Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of United Therapeutics Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of United Therapeutics Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
United Therapeutics Corporation Snapshot 5
United Therapeutics Corporation Overview 5
Key Information 5
Key Facts 5
United Therapeutics Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
United Therapeutics Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
United Therapeutics Corporation - Pipeline Products Glance 12
United Therapeutics Corporation - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
United Therapeutics Corporation - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
United Therapeutics Corporation - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
United Therapeutics Corporation - Drug Profiles 16
dinutuximab 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
beraprost sodium SR 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PLX-PAD 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
UV-4B 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
esuberaprost sodium ER 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Human Antibody Based Vaccines 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Insulin Producing Islet Cells 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules for Viral Infections 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
United Therapeutics Corporation - Pipeline Analysis 31
United Therapeutics Corporation - Pipeline Products by Target 31
United Therapeutics Corporation - Pipeline Products by Route of Administration 32
United Therapeutics Corporation - Pipeline Products by Molecule Type 33
United Therapeutics Corporation - Pipeline Products by Mechanism of Action 34
United Therapeutics Corporation - Recent Pipeline Updates 35
United Therapeutics Corporation - Dormant Projects 39
United Therapeutics Corporation - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
8H-9 40
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom 40
UT-231B 40
United Therapeutics Corporation - Company Statement 41
United Therapeutics Corporation - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

United Therapeutics Corporation, Key Information 5
United Therapeutics Corporation, Key Facts 5
United Therapeutics Corporation - Pipeline by Indication, 2015 7
United Therapeutics Corporation - Pipeline by Stage of Development, 2015 8
United Therapeutics Corporation - Monotherapy Products in Pipeline, 2015 9
United Therapeutics Corporation - Partnered Products in Pipeline, 2015 10
United Therapeutics Corporation - Partnered Products/ Combination Treatment Modalities, 2015 11
United Therapeutics Corporation - Pre-Registration, 2015 12
United Therapeutics Corporation - Phase III, 2015 13
United Therapeutics Corporation - Phase I, 2015 14
United Therapeutics Corporation - Preclinical, 2015 15
United Therapeutics Corporation - Pipeline by Target, 2015 31
United Therapeutics Corporation - Pipeline by Route of Administration, 2015 32
United Therapeutics Corporation - Pipeline by Molecule Type, 2015 33
United Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2015 34
United Therapeutics Corporation - Recent Pipeline Updates, 2015 35
United Therapeutics Corporation - Dormant Developmental Projects,2015 39
United Therapeutics Corporation - Discontinued Pipeline Products, 2015 40
United Therapeutics Corporation, Other Locations 44
United Therapeutics Corporation, Subsidiaries 44